blinatumomab – Medxy AI

Low-dose Blinatumomab Therapy in Multidrug-Resistant Rheumatoid Arthritis: A Case Series Analysis

By MedXY 08/16/2026

A case series assessing the safety and efficacy of low-dose blinatumomab in 15 patients with multidrug-resistant rheumatoid arthritis showed synovial B-cell depletion, reduced disease activity, and improved response to previously ineffective DMARDs.

Hematology-Oncology news

Blinatumomab Consolidation in High-Risk Ph-Negative B-Cell Acute Lymphoblastic Leukemia: Insights from the GRAALL-2014/B-QUEST Study

By MedXY 07/20/2026

The GRAALL-2014/B-QUEST study demonstrates that integrating blinatumomab into consolidation and maintenance therapy significantly improves outcomes for adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

$Subcutaneous Blinatumomab in Relapsed/Refractory B-ALL: Clinical Promise and the Future of Delivery Modalities$

Clinical Updates Hematology-Oncology news Specialties

Subcutaneous Blinatumomab in Relapsed/Refractory B-ALL: Clinical Promise and the Future of Delivery Modalities

By MedXY 08/02/2025

Subcutaneous blinatumomab demonstrates promising efficacy and manageable safety in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with potential to shift future administration paradigms.